Article (Scientific journals)
Evaluation of the efficacy and the safety of parenteral sulbactam/ampicillin folllowed by oral sultamicillin for paediatric infections.
Mbonda, E; DRESSE, Marie-Françoise; Geubelle, F
1992In Acta Therapeutica, 18, p. 1-6
 

Files


Full Text
26A Mbonda.pdf
Publisher postprint (1.99 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Paediatric infections; betalactamase; parenteral sulbactam/ampicillin; oral sultamicillin
Abstract :
[en] The efficacy and the safety of parenteral sulbactam/ampicillin followed by oral sultamicillin* has been evaluated in 41 children aged between 0.5 and 15 years presenting with various infections.Overall clinical and bateriologial success was achieved in 92% of evaluable cases; 97% of 22 pathogens isolated in these patients were eradicated. Adverse reactions were pain at the intramuscular injections site (7%) which was minimized by concurrent injection of lidocaine. Gastro-intestinal disturbances with soft stools were common during oral sultamicillin therapy. Laboratory tests remained normal. Parental sulbactam/ampicillin followed by oral sultamicillin is useful therapy for the treatment of serious non-life-threatening paediatric infections.
Disciplines :
Immunology & infectious disease
Pharmacy, pharmacology & toxicology
Pediatrics
Author, co-author :
Mbonda, E
DRESSE, Marie-Françoise ;  Centre Hospitalier Universitaire de Liège - CHU > Service de pédiatrie (CHR)
Geubelle, F
Language :
English
Title :
Evaluation of the efficacy and the safety of parenteral sulbactam/ampicillin folllowed by oral sultamicillin for paediatric infections.
Publication date :
1992
Journal title :
Acta Therapeutica
ISSN :
0378-0619
Publisher :
Acta Therapeutica, Bruxelles, Belgium
Volume :
18
Pages :
1-6
Available on ORBi :
since 29 May 2016

Statistics


Number of views
72 (1 by ULiège)
Number of downloads
59 (0 by ULiège)

Bibliography


Similar publications



Sorry the service is unavailable at the moment. Please try again later.
Contact ORBi